Tamoxifen Tales
Suggestions for Scientific Survival
- 1st Edition - January 12, 2022
- Author: V. Craig Jordan
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 5 0 5 1 - 3
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 9 6 1 7 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 5 9 7 2 - 1
Tamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlight… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTamoxifen Tales: Suggestions for Scientific Survival presents a case study describing the academic journey of teams behind major advances in medical sciences, highlighting lessons learned that are applicable to the next generation of scientists. This book provides a manual on the successful mentoring of young scientists, including stories describing how training experience shaped careers to become leaders in academia and the pharmaceutical industry. The book documents Professor V. Craig Jordan’s 50-year career in medical sciences that led to the discovery and development of Selective Estrogen Receptor Modulators (SERMs), which became the standard of women’s healthcare around the world.
Additionally, it illustrates the versatility of a scientist with a commitment to serving societies. This important resource will be a useful and interesting book for established medical scientists, research mentors and advanced students wanting to chart a successful and impactful research career.
- Highlights lessons learned from the journey behind discovery science that are applicable to the scientific journey of the next generation of scientists
- Provides a manual on the successful mentoring of young scientists to become leaders in academia and the pharmaceutical industry
- Examines cancer treatment based on a personal determination to challenge at the frontiers of the science and to relate to personal life experience
- Includes references for further research reading
Medical scientists, postgraduates, academics in medical sciences. People interested in the history of medical discovery and leadership development
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Dedication
- Dedication
- About the author
- Acknowledgments
- The scope and foundation steps in a career
- Foreword—Melvyn Bragg
- None
- Why write this book?
- Number 1: “Have a dream” (mine was to develop a drug, any drug, to treat cancer)
- Number 5: “Be the most enthusiastic person you know” (I am a bit too enthusiastic for most people)
- Number 8: “Them that stick it out are them that win” (I never stop trying)
- Number 9: “That little bit extra” (My life's philosophy is total commitment to achieve the goal)
- Prelude
- Chapter 1. Beginnings
- Going to America
- My early years in Cheshire
- Growing up in Bramhall
- Chapter 2. Leeds University: foundation of a career
- Postscript on Career Preparation for a Degree in Pharmacy from the Department of Pharmacology at Leeds
- Chapter 3. The chance to be a Ph.D. student at the University of Leeds
- Chapter 4. Two antiestrogenic strategies to treat breast cancer at the Worcester Foundation
- Breakthrough
- Postscript
- Chapter 5. A new strategy: long-term adjuvant tamoxifen treatment and other discoveries at the University of Leeds
- Chemoprevention
- The move to adjuvant therapy
- Unanticipated sadness and success of Alderley Park
- An investigation of the molecular mechanism of action of tamoxifen
- A time of major decisions
- Chapter 6. Tamoxifen's patenting problems in America, which created a “cancer treatment company”
- Chapter 7. Two opportunities on different continents
- Chapter 8. The good, the bad and the ugly of tamoxifen at Wisconsin
- Animal models—finding the bad about tamoxifen
- Linking tamoxifen with endometrial cancer
- Chapter 9. “Sliding Doors” and serendipity
- Chapter 10. South to Northwestern in Chicago
- The research plan to build a new Tamoxifen team at the Robert H. Lurie Cancer Center
- Educational outreach and research priorities at the Robert H. Lurie Comprehensive Cancer Center
- Deciphering the molecular mechanism of antiestrogen action and the new science of estrogen-induced apoptosis
- Extensive animal models of estrogen-induced apoptosis to decipher pathways and clinical utility
- Consolidating the financial flow with federal grants
- Celebrations around the Diana, Princess of Wales Professorship in Cancer Research
- A surprise honor
- The glamor of the “Big Three of Cancer Research”: Bristol Myers Squibb Award (2001), American Cancer Society Medal of Honor (2002), and the Charles F. Kettering Prize (clinical) from General Motors (2003): a triumph for the Robert H. Lurie Comprehensive Cancer Center at its zenith
- Conclusion
- Chapter 11. Forward to the Fox Chase Cancer Center in Philadelphia
- The Fox Chase Cancer Center Tamoxifen Team
- Peer recognition at Fox Chase Cancer Center for the accomplishments of the Tamoxifen Teams
- Chapter 12. Get out and go to Georgetown
- Building my Tamoxifen Team at Georgetown
- The Peacock Café, Georgetown
- Graduate students at Georgetown
- Chapter 13. Closing the circle on Tamoxifen Tales
- Chapter 14. “If I wanted to buy your brain, what would that cost?”: rebirth at M.D. Anderson Cancer Center
- Ping Fan completes our molecular mechanism to explain the increase in breast cancers in the CEE/MPA treated women 10 years after menopause in the WHI
- Philipp Maximov, Balkees Abderrahman, and Ramona Curpan define the molecular mechanism of action of the partial estrogen agonist bisphenol to delay apoptosis
- Balkees Abderrahman and Ramona Curpan define the molecular mechanism of action of the clinically relevant estrogen mimic TTC-352
- Battle with the “enemy within” 4 years later
- Recognition from national academies and major international awards that acknowledge a change in medicine while at the MD Anderson Cancer Center
- Recognition from professional academic societies
- Recognition, honorary appointments or honorary degrees, etc
- Chapter 15. “Invest in the young”
- Chapter 16. Scientific survival suggestions
- Chapter 17. An account of students obtaining a Ph.D. degree (or an MD for physicians in the British System) while in the Tamoxifen Team over the last 50 years
- Clive J. Dix, Department of Pharmacology, University of Leeds, 1976–79; ICI Pharmaceuticals Division Research Scholar
- Anna T. Riegel (Neé Tate), McArdle Laboratory for Cancer Research, University of Wisconsin, 1980–83; Fulbright Hays Scholar
- Stewart D. Lyman, McArdle Laboratory, University of Wisconsin, 1982–84
- Ethel M. Cormier, Molecular and Cellular Biology Graduate Program, University of Wisconsin, 1982–88
- Marco M. Gottardis, Department of Human Oncology, University of Wisconsin, 1983–89
- Catherine S. Murphy, Department of Human Oncology, University of Wisconsin, 1984–90
- Meei-Huey Jeng, Department of Human Oncology, University of Wisconsin, 1987–92
- Shun-Yuan Jiang, Department of Human Oncology, University of Wisconsin, 1987–92; Scholarship from the Taiwanese Ministry of Defense
- Doug M. Wolf, Department of Human Oncology, University of Wisconsin, 1988–93; Susan G. Komen graduate student
- John J. Pink, Department of Human Oncology, University of Wisconsin, 1990–95
- William H. Catherino, Department of Human Oncology, University of Wisconsin, MD/Ph.D. program, 1991–95
- Jennifer I. MacGregor-Schafer, Northwestern University, Department of Defense Graduate Student Training Program, Chicago, IL, 1995–2001
- Ruth M. O'Regan, University College, Dublin, Ireland, 1996–2000 (Faculty in Medical Oncology, Northwestern University, Chicago, IL)
- Rita C. Dardes, Department of Obstetrics and Gynecology, University of Sao Paulo, Brazil, 1998–2001
- Philipp Y. Maximov, N.I. Pirogov Russian National Medical Research University, Russia, 2006–10
- Ifeyinwa Obiorah, Department of Oncology, V.T. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 2010–14
- Elizabeth Sweeney, Department of Oncology, V.T. Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 2011–14
- Balkees Abderrahman, Department of Breast Medical Oncology, University of Texas, MD, Anderson Cancer Center/University of Leeds, split site model C applicants of very high quality (inaugural candidate) 2017–20
- Chapter 18. Case studies: in their own words
- Clive James Dix, Ph.D.
- Anna Riegel, Ph.D.
- Marco Gottardis, Ph.D.
- Andreas Friedl, MD
- Doug Wolf, Ph.D.
- Shun-Yuan Jiang, Ph.D.
- William H. Catherino, MD, Ph.D.
- Anait S Levenson, MD, Ph.D.
- Debra A. Tonetti, Ph.D.
- Rita Dardes, MD, Ph.D.
- Clodia Osipo, Ph.D.
- Ruth O'Regan, MD
- David Bentrem, MD
- Joan Lewis-Wambi, Ph.D.
- Philipp Y. Maximov, MD, Ph.D., MBA
- Ping Fan, MD, Ph.D.
- Balkees Abderrahman MD, Ph.D.
- Index
- No. of pages: 312
- Language: English
- Edition: 1
- Published: January 12, 2022
- Imprint: Academic Press
- Hardback ISBN: 9780323850513
- Paperback ISBN: 9780323996174
- eBook ISBN: 9780323859721
VJ
V. Craig Jordan
V. Craig Jordan is Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Previously, he was Scientific Director and Vice Chairman of Oncology at the Lombardi Comprehensive Cancer Center of Georgetown University. Jordan was the first to discover the breast cancer prevention properties of tamoxifen and the scientific principles for adjuvant therapy with antihormones. More recently his work has branched out into the prevention of multiple diseases in women with the discovery of the drug group, selective estrogen receptor modulator (SERMs). Currently, he plans to develop a new Hormone Replacement Therapy (HRT) for post-menopausal women that prevents breast cancer and does not increase the risk of breast cancer. In 2019 he was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II for services to women’s health.
Affiliations and expertise
Professor of Breast Medical Oncology, Professor of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USARead Tamoxifen Tales on ScienceDirect